PSMA-based PET Imaging for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.
Who Is on the Research Team?
Curtiland Deville, M.D.
Principal Investigator
The SKCCC at Johns Hopkins
Are You a Good Fit for This Trial?
This trial is for men over 18 with newly diagnosed prostate cancer, graded Gleason 8-10, who are planning to have radiation and ADT. They must be medically fit for these treatments and at least 10 days post-prostate biopsy. Men already on hormone therapy or those who've had chemotherapy, investigational therapies, or prior pelvic radiation can't participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Imaging
Participants undergo baseline DCFPyL PET-MRI fusion or PET/MRI imaging
Treatment
Participants receive 2-3 months of androgen deprivation therapy (ADT) with follow-up imaging
Follow-up Imaging
Participants undergo follow-up DCFPyL PET-MRI fusion or PET/MRI imaging to assess response to ADT
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- 18F-DCFPyL
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
National Cancer Institute (NCI)
Collaborator